Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals

AIDS

Volumn 27, Issue 3, 2013, Pages 459-468

  Suneja, Gita ^a   Shiels, Meredith S ^b   Melville, Sharon K ^c   Williams, Melanie A ^c   Rengan, Ramesh ^a   Engels, Eric A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

carcinoma; healthcare disparities statistics; HIV infections virology; HIV pathogenicity; lung neoplasms; lung neoplasms therapy; nonsmall cell lung therapy

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; EUROPEAN AMERICAN; FEMALE; GENDER; HEALTH CARE DISPARITY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RACE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTHCARE DISPARITIES; HIV INFECTIONS; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872282305     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ad56e     Document Type: Article

References (52)

1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753-762.
2. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-622.
3. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383-1388.
4. Nguyen ML, Farrell KJ, Gunthel CJ. Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep 2010; 12:46-55.
5. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207-213.
6. Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDs 2007; 21:458-468.
7. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14:824-835.
8. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432.
9. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23:2337-2345.
10. Lavole A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J. Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006; 51:1-11.
11. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 2008; 8:605-615.
12. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 nonsmall cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60:615-622; discussion 622-623.
13. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III nonsmall-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
14. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III nonsmall-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374:379-386.
15. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced nonsmall-cell lung cancer. J Clin Oncol 2010; 28:2181-2190.
16. NCCN Clinical Practice Guidelines in Oncology Non-Small-Cell Lung Cancer v 2. 2012. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf [Accessed 4 January 2012].
17. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271.
18. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10:467-474.
19. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293-299.
20. Lavole A, Chouaid C, Baudrin L, Wislez M, Raguin G, Pialoux G, et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with nonsmall-cell lung cancer. Lung Cancer 2009; 65:345-350.
21. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43:47-55.
22. Pakkala S, Chen Z, Rimland D, Owonikoko TK, Gunthel C, Brandes JR, et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118:164-172.
23. Alshafie MT, Donaldson B, Oluwole SF. Human immunodeficiency virus and lung cancer. Br J Surg 1997; 84:1068-1071.
24. Bertolaccini L, Lybéris P, Soncini S, Perri GD, Manno E. Clinical characteristic lung cancer in HIV-infected patients. Therapy 2008; 6:903-906.
25. Flores MR, Sridhar KS, Thurer RJ, Saldana M, Raub WA Jr, Klimas NG. Lung cancer in patients with human immunodeficiency virus infection. Am J Clin Oncol 1995; 18:59-66.
26. Karp J, Profeta G, Marantz PR, Karpel JP. Lung cancer in patients with immunodeficiency syndrome. Chest 1993; 103:410-413.
27. Powles T, Thirwell C, Newsom-Davis T, Nelson M, Shah P, Cox S, et al. Does HIV adversely influence the outcome in advanced nonsmall-cell lung cancer in the era of HAART? Br J Cancer 2003; 89:457-459.
28. Spano JP, Massiani MA, Bentata M, Rixe O, Friard S, Bossi P, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol 2004; 21:109-115.
29. Spina M, Sandri S, Serraino D, Gobitti C, Fasan M, Sinicco A, et al. Therapy of nonsmall-cell lung cancer (NSCLC) in patients with HIV infection. GICAT. Cooperative Group on AIDS and Tumors. Ann Oncol 1999; 10 (Suppl 5):S87-S90.
30. Tirelli U, Spina M, Sandri S, Serraino D, Gobitti C, Fasan M, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000; 88:563-569.
31. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996; 15:325-339.
32. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
33. Organization WH. International Classification of Diseases for Oncology. 3rd ed. (ICD-O-3). http://www.who.int/classifica tions/icd/adaptations/oncology/ en/[Accessed 4 January 2012].
34. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010; 102:1584-1598.
35. Texas Department of State Health Services. 2010 Texas Integrated Epidemiologic Profile for HIV/AIDS Prevention and Services Planning (Publication No. E13-11937).
36. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153:452-460.
37. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care: JANAC 1997; 8:43-54.
38. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002; 94:334-357.
39. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341:1198-1205.
40. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. Thorax 1996; 51:564-568.
41. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of nonsmall-cell lung cancer. J Clin Oncol 2004; 22:3261-3268.
42. Costleigh BJ, Miyamoto CT, Micaily B, Brady LW. Heightened sensitivity of the esophagus to radiation in a patient with AIDS. Am J Gastroenterol 1995; 90:812-814.
43. Leigh BR, Lau DH. Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Am J Clin Oncol 1998; 21:479-481.
44. Mani D, Haigentz M, Aboulafia DM. Lung cancer in HIV infection. Clin Lung Cancer 2011; 13:6-13.
45. Makinson A, Tenon J-C, Eymard-Duvernay S, Pujol J-L, Allavena C, Cuzin L, et al. Human immunodeficiency virus infection and nonsmall cell lung cancer: survival and toxicity of antineoplas-tic chemotherapy in a cohort study. J Thorac Oncol 2011; 6:1022-1029.
46. Cadranel J, Garfield D, Lavole A, Wislez M, Milleron B, Mayaud C. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 2006; 61:1000-1008.
47. Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J. Interactions between cytotoxic chemotherapy and anti-retroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 2010; 5:562-571.
48. Pakkala S, Ramalingam SS. Lung cancer in HIV-positive patients. J Thorac Oncol 2010; 5:1864-1871.
49. See AP, Zeng J, Tran PT, Lim M. Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. Radiat Oncol 2011; 6:25.
50. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008; 26:1027-1032.
51. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with meta-static nonsmall-cell lung cancer. N Engl J Med 2010; 363:733-742.
52. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002; 20:1786-1792.